Related Experiment Video
Updated: Mar 2, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
[Application of improved regional citrate anticoagulation in continuous hemofiltration in children]
1Intensive Care Unit, the Children's Hospital, Chongqing Medical University; Ministry of Education Key Laboratory of Child Development and Disorders; Key Laboratory of Pediatrics in Chongqing; Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Chongqing 400014, China.
Insights
Regional citrate anticoagulation with calcium hemofiltration basic solution is safe and effective for continuous hemofiltration in children. This method achieved good anticoagulation and filter lifespan without significant clotting events.
Area of Science:
- Pediatric Nephrology
- Critical Care Medicine
- Renal Replacement Therapy
Background:
- Continuous hemofiltration (CHF) is a vital renal replacement therapy for critically ill children.
- Regional citrate anticoagulation (RCA) is an alternative to systemic anticoagulation, potentially reducing bleeding risks.
- The use of calcium-containing hemofiltration basic solutions in pediatric RCA-CHF requires further investigation.
Purpose of the Study:
- To evaluate the safety and efficacy of regional citrate anticoagulation using a commercial calcium hemofiltration basic solution in pediatric continuous hemofiltration.
- To determine optimal parameter settings for blood flow, citrate, sodium bicarbonate, calcium, and filtered solution.
- To monitor anticoagulation targets, electrolyte balance, acid-base status, and filter lifespan.
Main Methods:
- Retrospective analysis of 18 pediatric patients undergoing RCA-CHF (excluding hepatic failure and septic shock).
- Utilized a commercial calcium hemofiltration basic solution as the replacement fluid.
- Monitored blood gas analysis, electrolytes, coagulation tests, and filter performance throughout treatment.
Main Results:
- Successfully applied RCA-CHF for 734.5 hours with an average filter lifespan of 25±11 hours and no significant clotting events.
- Established parameter settings: QCi=1.8×QB, QCa=0.12×QB, QSB=0.01×Qf.
- Achieved target extracorporeal and intracorporeal ionized calcium levels in 89.3% and 96.4% of measurements, respectively. Mildly elevated HCO3- was the most common complication (51.8%).
Conclusions:
- Commercialized displacement fluid containing calcium can be safely and simply used for regional citrate anticoagulation in continuous hemofiltration in children.
- This approach demonstrates effective anticoagulation and acceptable filter durability.
- The method offers a viable alternative for anticoagulation in pediatric continuous hemofiltration.
Abstract:
Objective: To investigate the application of regional citrate anticoagulation with calcium hemofiltration basic solution in continuous hemofiltration in children. Method: The clinical data of 18 patients with citrate anticoagulation in continuous hemofiltration in children, excluding the hepatic failure and septic shock cases, were analyzed retrospectively, from September 2015 to August 2016 in Intensive Care Unit of the Children's Hospital of Chongqing Medical University.The commercial calcium hemofiltration basic solution was used as displacement liquid . The blood gas analysis, electrolyte, four coagulation tests during the treatment and the corresponding relations of quantity of blood flow(QB), quantity of citrate flow(QCi), quantity of sodium bicarbonate flow(QSB), quantity of calcium flow(QCa), quantity of filtered solution flow (Qf) were monitored. Meanwhile, the blood gas analysis, electrolyte, four coagulation tests, useful life of filter, bleeding and clotting events internal and external before, during and after the treatments were monitored, too. And the common complications of citrate anticoagulation, such as hypocalcaemia, metabolic alkalosis, citrate accumulation and hypernatremia were observed. Result: Continuous hemofiltration was applied in 18 patients for 734.5 hours, and the average useful life of filter was (25±11)h.There was no obvious clotting event. There were 168 groups of datum of the blood gas analysis, electrolyte, four coagulation tests during the treatment and the relationships of QB, QCi, QSB, QCa, Qf had been collected. The relationships of the initial parameter settings of QB, QCi, QSB, QCa and Qf were concluded as QCi=1.8×QB, QCa=0.12×QB, QSB=0.01×Qf . There were 150 times(89.3%)of extracorporeal ionized calcium(iCa(E)(2+)) and 162 times(96.4%) of intracorporal ionized calcium(iCa(I)(2+)) reached the anticoagulation target. Although all the comparisons of Na(+) ((136.2±4.1)vs.(138.2±2.4)vs.(138.5±3.9)mmol/L), iCa(2+) ((1.07±0.11)vs.(1.21±0.12)vs.(1.17±0.09)mmol/L), HCO(3)(-) ((22±4)vs.(28±5)vs. (26±4)mmol/L) among before, during and after treatment had significant difference(F=6.414, 18.950, 19.151; P=0.002, 0.000, 0.000). Each mean parameter was within the nearly normal range, except that the HCO(3)(-) increased slightly. High HCO(3)(-) was the most common complications, which happened 87 times (51.8%) during the treatment and 11 cases(37.9%) after the treatment. There was none with refractory hypocalcemia and total ionized calcium(TCa(2+) )/iCa(2+) above 2.5, which hints the accumulation of citrate. Conclusion: The commercialized displacement liquid containing calcium can be used in RCA-CHF in children safely and simply.
More Related Videos
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
04:55Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Acute Kidney Injury V: Interprofessional Care